Oyavas (Bevacizumab)

Bevacizumab, the active ingredient in Oyavas, is a monoclonal antibody presented as a strength/form for intravenous use. It inhibits abnormal blood vessel growth in various cancers and is administered under the supervision of oncology specialists. GNH USA supplies Oyavas as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oyavas as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Oyavas is a monoclonal antibody that targets angiogenesis pathways in several solid tumours.

- Colorectal cancer: Improves survival when combined with chemotherapy. - Non‑small cell lung cancer: Used with carboplatin‑pemetrexed regimens. - Glioblastoma multiforme: Used in combination with radiotherapy and temozolomide. - Metastatic breast ​  ​  ​  ​  ​  ​ ​ ​ ​:  Provides            ​  ​  ​   ​  ​  ​  ​  benef  ​      ​  ​  ​  ​  ​  ​ ​  ​  ​  ​ ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​​ ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ ​ ​

The        … 

...

metatitle